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Abstract: ABSTRACT
Background Only a minority of intracranial aneurysms rupture to cause subarachnoid
haemorrhage.
Objective We tested the hypothesis that unruptured aneurysms have different
characteristics and risk factor profiles compared to ruptured aneurysms.
Methods We recruited patients with unruptured aneurysms or aneurysmal
subarachnoid haemorrhage at 22 UK hospitals between 2011-2014. Demographic,
clinical, and imaging data were collected using standardized case report forms. We
compared risk factors using multivariable logistic regression.
Results 2334 patients (1729 with aneurysmal subarachnoid haemorrhage, 605 with
unruptured aneurysms) were included (mean age 54.22 years). In multivariable
analyses, the following variables were independently associated with rupture status:
black ethnicity (OR 2.42; 95% CI 1.29-4.56; compared to white); aneurysm location
(anterior cerebral artery/anterior communicating artery [OR 3.21; 95% CI 2.34-4.40],
posterior communicating artery [OR 3.92; 95% CI 2.67-5.74], or posterior circulation
[OR 3.12; 95% CI 2.08-4.70], compared to middle cerebral artery). The following
variables were inversely associated with rupture status: antihypertensive medication
(OR 0.65; 95% CI 0.49-0.84), hypercholesterolemia (0.64 OR; 95% CI 0.48-0.85),
aspirin use (OR 0.28; 95% CI 0.20-0.40), internal carotid artery location (OR 0.53; 95%
CI 0.38-0.75), and aneurysm size (per mm increase) (OR 0.76; 95% CI 0.69-0.84).
Conclusion We show substantial differences in patient and aneurysm characteristics
between ruptured and unruptured aneurysms. These findings support the hypothesis
that different pathological mechanisms are involved in the formation of ruptured
aneurysms and incidentally detected unruptured aneurysms. The potential protective
effect of aspirin in the two cohorts might justify randomized prevention trials in patients
with unruptured aneurysms.
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Additional Information:
Question Response
Significance of the Work:
Please include a brief statement
summarizing the significance of the work
and in particular how it differs from and
advances existing literature.
Aneurysmal subarachnoid haemorrhage (SAH) is a devastating subset of stroke,
occurring in relatively young people with a high mortality rate. Understanding risk
factors may be helpful in identifying patients at high risk for aneurysmal SAH and
consequently prevention. In our large multicentre case-control study, we have
identified differing potential risk factors when comparing unruptured intracranial
aneurysms with aneurysms causing SAH; in particular, aspirin use was found to be
protective, independent of confounding by indication, and might merit further
investigation. Our findings are relevant for neurologists and neurosurgeons when
making clinical decisions in patients with an unruptured intracranial aneurysm.
Compliance with Research Reporting
Guidelines:
Neurosurgery endorses several reporting
guidelines and requires authors to submit
their research articles in accordance with
the appropriate guideline statement(s)
and checklist(s). Completed applicable
checklists and flow diagrams must be
included with submissions.
Research articles that must be submitted
according to the appropriate reporting
guideline(s) include, but are not limited to:
randomized trials, systematic reviews,
meta-analyses of interventions, meta-
analyses of observational studies,
diagnostic accuracy studies, and
observational epidemiological studies (eg,
case series, cohort, case-control, and
cross-sectional studies). Consult the
EQUATOR Network, which maintains a
useful, up-to-date list of guidelines as they
are published, with links to articles and
checklists: http://www.equator-
network.org.
Please confirm below that information is
reported according to the relevant
reporting guideline(s) and any required
materials are included with the
submission:
Yes - Submission Adheres to Appropriate Reporting Guideline(s) and Applicable
Checklists/Materials Are Included
Please indicate which reporting
guideline(s) the study adheres to (eg,
STROBE, PRISMA, CONSORT).
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Research Reporting Guidelines:
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guidelines and requires authors to submit
their research articles in accordance with
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and checklist(s). Completed applicable
checklists and flow diagrams must be
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according to the appropriate reporting
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analyses of observational studies,
diagnostic accuracy studies, and
STROBE
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20th September 2016  
Dr Nelson M. Oyesiku, MD PhD, FACS, Editor-in-Chief 
Editor, Neurosurgery 
 
Dear Dr Oyesiku, 
 
Re:  Characteristics of unruptured compared to ruptured intracranial aneurysms: a 
multicentre case-control study 
 
We would be grateful if the above paper could be considered for publication in Neurosurgery as an 
article. Aneurysmal subarachnoid haemorrhage (SAH) is a devastating subset of stroke, occurring in 
relatively young people with a high mortality rate. Understanding risk factors may be helpful in 
identifying patients at high risk for aneurysmal SAH and consequently prevention. In our large 
multicentre case-control study, we have identified differing potential risk factors when comparing 
unruptured intracranial aneurysms with aneurysms causing SAH; in particular, aspirin use was 
found to be protective, independent of confounding by indication, and might merit further 
investigation. Our findings are relevant for neurologists and neurosurgeons when making clinical 
decisions in patients with an unruptured intracranial aneurysm.  
 
I take full responsibility for the data, the analyses and interpretation, and the conduct of the 
research; I have full access to all of the data; the author has the right to publish any and all data 
separate and apart from any sponsor. A regional review board has approved the use of human 
subjects for this study. 
 
All authors have read and approved the submitted manuscript; the manuscript has not been 
submitted elsewhere nor published elsewhere in whole or in part. I sign for and accept responsibility 
for this material on behalf of all co-authors. None of the authors have any conflict of interest to 
report.  
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The Institute of Neurology promotes teaching and research of the highest quality in neurology and the neurosciences. 
 
 
This study was conducted in compliance with the current version of the Declaration of Helsinki, and 
GCP as well as all national legal and regulatory requirements. 
 
The GOSH study is funded by the Stroke Association. This work was partly undertaken at 
UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR 
Biomedical Research Centres funding scheme.  
 
Yours sincerely,  
 
 
David Werring PhD FRCP FESO 
Professor of Clinical Neurology 
Consultant Neurologist  
RESPONSE TO REVIEWERS 
 
Dear reviewers 
 
RE: Characteristics of unruptured compared to ruptured intracranial 
aneurysms: a multicentre case-control study 
 
We are grateful for the opportunity to resubmit a secondary revised version. Our itemized 
point-by-point responses are given below, and are underlined in our revised manuscript. 
 
Reviewer 1: 
 
This revised manuscript, which describes a case control study identifying differences in 
ruptured and unruptured aneurysms, has been revised to adequately address our 
comments. This new version better defines the limitations of their study, especially 
regarding potential biases in the study groups. Even with its flaws, this study contributes 
to our current body of data and will further discussion on differences between ruptured 
and unruptured aneurysms. 
 
We thank the reviewer for the useful comments and improvement on our manuscript. 
 
Reviewer 2: 
 
The authors did a great job addressing the reviewer’s concerns. 
 
We thank the reviewer for the useful comments and improvement on our manuscript. 
 
Reviewer 3: 
 
1. The manuscript has now been improved by deleting obvious concerns and faults. 
However, the study design and patient selection predisposes yet for misconceptions which 
are not necessarily true but preferably association between different confounding factors 
which are difficult to be controlled for. Further analyses are needed. 
 
We thank the reviewer for the useful comments and improvement on our manuscript. We have 
checked that we have undertaken all of the analyses suggested (see our response to point 4, 
below).  
 
2. The study consists of 2334 patients (1729 with aneurysmal subarachnoid haemorrhage, 
605 with unruptured aneurysms (UIAs)) were included (mean age 54.22 years). Patients 
with UIAs had clearly larger aneurysm than has previously been published (see ref 1. 
Vlak et al.) meaning that this population with UIAs is a more selected one than in previous 
studies. 
 
We agree with this point. Indeed, we had a larger mean UIA size compared to Vlak et al. which 
could indicate selection bias, a limitation of any hospital-based study. However, an important 
Response to Reviewers
strength of our study compared to the Vlak et al study is that we had less missing data: in our 
study, 605 UIA cohort, aneurysm size was available in 544 patients (90%); in comparison, the 
meta-analysis of Vlak et al., of 1450 patients included in the meta-analysis UIA aneurysm size 
was only available in 368 (25%). We have added a statement in the discussion (Page 6, lines 
178-182).  
 
3. Patients with high BP values, long-term hypertension and large aneurysms die more 
likely than survive after SAH and do not reach treatment in secondary and tertiary 
clinics. For this issue there is only one study (Juvela S. Prehemorrhage risk factors for 
fatal intracranial aneurysm rupture. Stroke 2003;34:1852-1857). Some autopsy studies 
also suggest that patients with ruptured MCA aneurysms with space occupying are more 
common autopsy studies than in clinical studies. So patients with hypertension, large 
aneurysms and MCA aneurysms may be underestimated in ruptured aneurysm group. 
 
We agree that our study cannot include patients with severe SAH who die before reaching 
hospital, and that these patients might have different characteristics to those included (e.g 
larger aneurysms or co-morbidities), potentially introducing selection bias. This is a limitation 
of any study on ruptured aneurysms, which we acknowledge and discuss (Page 6, lines 200-
202).  
 
4. Patients with UIAs were older, had more diseases and medications (hypertension and 
antihypertensive medication, diabetes, hypercholesterolemia and statin use, previous 
stroke, coronary artery disease, cardiac disease, and because of several vascular diseases 
and risk factors also aspirin use. All these factors were more common in patients with 
UIAs than in those with SAH. Authors have picked aspirin as a "protecting factor" for 
rupture. Only in Table 3 were odds ratios adjusted for one of these confounders, previous 
stroke, which had also a lower association with SAH! By which mechanism? The reason 
seems that in cross-sectional retrospective study factors may associate without a causal 
relationship. Very sick patients likely die of other diseases than of aneurysm rupture. 
Because authors have interviewed and collected data from patients authors should 
present also indications of aspirin treatment. Aspirin was used likely for vascular diseases 
which shorten life-expectancy. 
 
We thank the reviewer for addressing this important point. We can clarify that aspirin was 
shown to be “protective” in a pre-planned and systematic analysis, described in our methods, 
and was not specifically “picked”. We adjusted for all of the above-mentioned factors in a 
multivariable backward stepwise logistic regression analysis: diabetes, statin use, cardio-
vascular disease such as myocardial infarction, angina, and PVD. On page 7, lines 227-229 
we mention this: “even after fully adjusting for potential confounders (ischemic heart disease, 
peripheral vascular disease, and diabetes)…”. We agree that a cross-sectional study cannot 
prove causation, or mechanisms of association. We agree that association between previous 
stroke and unruptured aneurysms is unlikely to be causal; for example, one possibility is that 
patients with a stroke have more careful management of their vascular risk factors, which 
might reduce future rupture risk.  
 
Unfortunately, we cannot provide the detailed information about aspirin indication as 
requested by the reviewer. Nevertheless, the assumption can be made that patients either 
received aspirin due to an underlying cardiovascular condition (MI [35 on aspirin], angina 
[29 on aspirin], PVD [12 on aspirin], previous ischemic stroke [51 on aspirin], DM [34 on 
aspirin]) or as primary prevention (it has become a widespread practice of GP’s to start 
patients above a certain age on aspirin). One hypothesis why patients with UIA use aspirin 
more frequently is that there are actively investigated for other potential risk factors, i.e. 
cardiovascular risk factors. Therefore, these patients could potentially have higher levels of 
aspirin use.  
 
5. I am a little bit surprised that authors have not noted possibility of Berkson's bias in 
their study. A classic example is association of lung cancer both with smoking and yellow 
fingers. Yellow fingers may associate with lung cancer more significantly than smoking 
yes/no. I think that nobody can insist yellow fingers to cause lung cancer because it is not 
biologically plausible. This same seems to be here when authors assume that aspirin may 
prevent aneurysm bleeding. The only real treatment method is occlusion of aneurysm. 
 
We agree that Berkson’s bias might affect our results, as in any study where cases and controls 
are recruited from a hospital (so that controls may not reflect the full population outside 
hospital). It is also possible that some of our associations are not causal, as in the example 
given by the reviewer. However, we have performed careful and systematic adjustment for all 
potential confounding factors to minimise the effect of potential bias and confounding. Our 
discussion clearly acknowledges the potential selection bias in our hospital-based study.  
 
We also agree with the reviewers that the only definitive treatment of an UIA is its occlusion. 
However, our data and several other studies report an interesting potential protective effect of 
aspirin on aneurysm rupture1-3. Aneurysm wall inflammation might be reduced by the anti-
inflammatory properties of aspirin, which might attenuate growth and reduce rupture risk2. To 
prove or disprove this hypothesis, a randomized trial would be needed. Indeed, we note that 
such trials are planned (e.g. clinicaltrials.gov NCT03063541). Although we agree that we 
cannot conclude that aspirin can prevent UIA rupture, we think our data are nevertheless of 
interest in supporting further investigation of this idea.  
 
Therefore, it is unlikely that Berkson’s bias accounts for the possible effect of aspirin. The only 
way to definitively conclude whether aspirin does or does not have a protective effect is through 
a randomized controlled trial, which is beyond the scope of our study. 
 
6. Authors should reanalyze results of Table 3 adjusting all above mentioned 
cardiovascular diseases and risk factors for association between aneurysm groups to see 
whether aspirin use and hypercholesterolemia are true independent factors. It seems that 
aspirin use is a proxy of several other factors since, e.g. patients with diabetes commonly 
use aspirin to prevent ischemic diseases. If some diseases/factors are too uncommon to be 
tested factors these can be combined as factors such as cardiovascular diseases and 
cardiovascular risk factors. 
 
We agree that it is important to adjust for all of these factors (confounding by indication). We 
have therefore included all of them in our analyses (see page 7, lines 227-229 where we 
mention, “even after fully adjusting for potential confounders (ischaemic heart disease, 
peripheral vascular disease, and diabetes)”.  For the purposes of clarity, and in line with 
standard statistical practice, some of these factors which were not statistically significant do 
not appear in the final models in Table 2 and Table 3.   
 
7. Authors state in Discussion: "By contrast, the majority of stable unruptured 
aneurysms would be expected to have low rupture rates, even if this increases with 
increasing aneurysm size, consistent with observational data reporting that only a very 
small minority of incidentally detected unruptured aneurysms will rupture to cause 
aneurysmal SAH (incidence 9 in 206 100,000)." This statement is not true and most UIAs 
are smaller than those in this study. Incidence rate is right but UIAs grow with a rate of 
3-4% per year in a follow-up of even low-risk UIAs. These do not likely rupture because 
patients are dying of unrelated causes. However, if UIA is growing the rupture risk is 
clearly higher and more than 50% of growing UIAs are rupturing during follow-up 
(Juvela S, Poussa K, Porras M. Factors affecting formation and growth of intracranial 
aneurysms: a long-term follow-up study. Stroke 2001;32:485-491). This should be noted 
and cited in discussion since risky UIAs were not selected by aneurysm occlusion at 
baseline of follow-up n this study. This study also had highest study quality and lowest 
study bias according to recent meta-analyses of UIA growth (Brinjikji W, Zhu YQ, 
Lanzino G, Cloft HJ, Murad MH, Wang Z, Kallmes DF. Risk factors for growth of 
intracranial aneurysms: a systematic review and meta-analysis. Am J Neuroradiol 
2016;37:615-620; and Backes D, Rinkel GJ, Laban KG, Algra A, Vergouwen MD. 
Patient- and aneurysm-specific risk factors for intracranial aneurysm growth: systematic 
review and meta-analysis. Stroke 2016;47:951-957). 
 
We thank the reviewer for this comment and agree that the wording of our sentence was not 
fully clear (“By contrast, most stable unruptured aneurysms would be expected to have low 
rupture rates, even if this increases with increasing aneurysm size”). We have changed the 
wording and included a new sentence focused on the increase in size of a specific unruptured 
aneurysm. The reference has been added. Please see: 
- Page 6, lines 197-200. 
 
8. Comments on evidence of aspirin for treatment of UIAs are not based on unbiased high 
grade studies. Author has cited one post hoc study of ISUIA. One must remember that 
ISUIA was a highly selected patient population study with a low rupture risk UIAs. At 
baseline already 58% were excluded from follow-up because of an aneurysm occlusion 
and additional 32% were treated during follow-up before a possible rupture (see refs 22 
and 23). If 71% of patients with UIAs are excluded totally or partially from a short-term 
follow-up, the remaining patients are likely similar to those patients with UIAs in the 
present study, i.e. patients with several cardiovascular diseases or risk factors using 
aspirin and statins and thought not to be benefit from aneurysm treatment. Patient with 
risk factors for cardiovascular diseases and aspirin use likely die untimely and likely not 
from aneurysm rupture because of a shorter life-expectancy. Post hoc study used logistic 
regression which cannot also discriminate timing of deaths. These results cannot be 
generalized to all patients with UIAs. 
 
We agree with the reviewer that the level of evidence for the effectiveness of aspirin on 
prevention of aneurysm rupture is low. However, evidence exists that aspirin harbors a 
preventive effect (see our comment to point 5, above). The only way to definitely approach this 
is to conduct a randomized trial on patients with UIA and aspirin intake. We agree that the 
ISUIA data cannot be generalized to all populations of patients with UIAs.  
 
9. Authors underestimate risks of aspirin stating that it is safe. In a primary prevention 
study aspirin use decreased risk of myocardial infarction but increased 2-fold risk of 
hemorrhagic stroke, most likely primary intracerebral hemorrhage (ICH)(Steering 
Committee of the Physicians' Health Study Research Group. Final report on the aspirin 
component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135). 
In addition, pre-ictal use of aspirin increases case fatality after ICH (Thompson BB, Béjot 
Y, Caso V, Castillo J, Christensen H, Flaherty ML, et al. Neurology 2010; 75: 1333-1342). 
 
Patients with SAH have also used more aspirin before rupture than patients with other 
acute diseases (Juvela S, Hillbom M, Numminen H, Koskinen P. Cigarette smoking and 
alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. Stroke 
1993; 24: 639-646). Pre-SAH use of aspirin increases risk for early rebleeding (Juvela S. 
Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J 
Neurosurg 1995; 82: 945-952; and Toussaint L, G III, Friedman JA, Wijdicks EFM, 
Piepgras DG, Pichelmann MA, McIvere JI, et al. Influence of aspirin on outcome 
following aneurysmal subarachnoid hemorrhage. J Neurosurg 2004;101:921-925). 
 
We thank the reviewer for his useful comments regarding the safety of aspirin; we have tried 
to implement them into our discussion. We have added a statement regarding the potential 
adverse effects of aspirin on intracerebral haemorrhage and SAH outcome (Page 8, 238-239). 
We agree that no strong evidence exists on the net clinical benefit of aspirin in preventing 
aneurysm rupture, potential increase in hemorrhage severity or increase in frequency of 
hemorrhagic stroke. Only a randomized controlled trial would give us a definitive answer to 
this question.  
- Page 7/8, lines 236-239 
- Page 8, lines 245-246 
- Page 10, lines 319-320 
 
10. It is yet highly doubtful whether aspirin really prevents SAH. These aspects make it 
difficult to estimate whether (low risk) UIAs should be studied in a placebo-controlled 
randomized trial to see prevention of bleeding. Study may need to continue decades to 
see effect and compliance of aspirin/placebo intake for a long-term time may be modest 
when risks of gastrointestinal and intracranial bleedings are noted by patients. It is well-
known that appropriate completion of a randomized trial of any treatment is a time 
consuming and includes several difficulties. Recommendation of such trial without 
careful evaluation is not reasonable. 
 
We agree with the reviewer that randomized treatment trials are time consuming, cost-
consuming and might be very challenging due to the length of follow up. We note that a small 
proof-of-concept randomized trial has already been conducted2 and that others are planned 
(clinicaltrials.gov NCT03063541).  
 
Once again, we are most grateful for the carefully considered, thorough and constructive 
comments from the reviewer. We hope that the paper will be considered of interest to the 
readers of Neurosurgery and suitable for publication.   
 
Please contact us if further information is required.  
 
Yours sincerely, 
 
The author and co-authors 
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No Recommendation 
 
 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 
 
Introduction 
 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
 
Objectives 3 State specific objectives, including any prespecified hypotheses 
 
Methods 
 
Study design 4 Present key elements of study design early in the paper 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection 
 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable 
 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
 
Bias 9 Describe any efforts to address potential sources of bias 
 
Study size 10 Explain how the study size was arrived at 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen 
and why 
 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
 
 
(b) Describe any methods used to examine subgroups and interactions 
 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
 
  (e) Describe any sensitivity analyses 
 
Results 
 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed 
 
 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders 
 
 
(b) Indicate number of participants with missing data for each variable of interest 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 
 
 
Case-control study—Report numbers in each exposure category, or summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures 
 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
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confidence interval). Make clear which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 
 
Discussion 
 
Key results 18 Summarise key results with reference to study objectives 
 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence 
 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
 
Other information 
 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which 
the present article is based 
 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The 
STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal 
Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
4, 5
4
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ABSTRACT  1 
Background Only a minority of intracranial aneurysms rupture to cause subarachnoid 2 
haemorrhage. 3 
Objective We tested the hypothesis that unruptured aneurysms have different characteristics 4 
and risk factor profiles compared to ruptured aneurysms.  5 
Methods We recruited patients with unruptured aneurysms or aneurysmal subarachnoid 6 
haemorrhage at 22 UK hospitals between 2011-2014. Demographic, clinical, and imaging 7 
data were collected using standardized case report forms. We compared risk factors using 8 
multivariable logistic regression.  9 
Results 2334 patients (1729 with aneurysmal subarachnoid haemorrhage, 605 with 10 
unruptured aneurysms) were included (mean age 54.22 years). In multivariable analyses, the 11 
following variables were independently associated with rupture status: black ethnicity (OR 12 
2.42; 95% CI 1.29-4.56; compared to white); aneurysm location (anterior cerebral 13 
artery/anterior communicating artery [OR 3.21; 95% CI 2.34-4.40], posterior communicating 14 
artery [OR 3.92; 95% CI 2.67-5.74], or posterior circulation [OR 3.12; 95% CI 2.08-4.70], 15 
compared to middle cerebral artery). The following variables were inversely associated with 16 
rupture status: antihypertensive medication (OR 0.65; 95% CI 0.49-0.84), 17 
hypercholesterolemia (0.64 OR; 95% CI 0.48-0.85), aspirin use (OR 0.28; 95% CI 0.20-0.40), 18 
internal carotid artery location (OR 0.53; 95% CI 0.38-0.75), and aneurysm size (per mm 19 
increase) (OR 0.76; 95% CI 0.69-0.84). 20 
Conclusion We show substantial differences in patient and aneurysm characteristics between 21 
ruptured and unruptured aneurysms. These findings support the hypothesis that different 22 
pathological mechanisms are involved in the formation of ruptured aneurysms and 23 
incidentally detected unruptured aneurysms. The potential protective effect of aspirin in the 24 
two cohorts might justify randomized prevention trials in patients with unruptured aneurysms.  25 
 26 
Running Title 27 
Characteristics of aneurysm types 28 
 29 
Key words 30 
Characteristics, predisposition to rupture, risk factors, subarachnoid haemorrhage, unruptured 31 
intracranial aneurysms. 32 
33 
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INTRODUCTION 34 
 35 
About 3 % of the population have an unruptured intracranial aneurysm1 but only a minority 36 
rupture to cause a subarachnoid haemorrhage (SAH); the overall risk of subarachnoid 37 
haemorrhage for unruptured intracranial aneurysms is about 1% per year2. SAH causes 5% of 38 
all strokes3, yet, with young age of onset and approximately 50% mortality, it substantially 39 
reduces productive life-years4-6 despite improvements in risk stratification, imaging, surgical 40 
and intensive care treatment. Up to 76% of patients who survive have permanent cognitive 41 
deficits, and only 6-17% of survivors return to employment7. Hence, predicting (and 42 
reducing) the risk of rupture of an intracranial aneurysm is an important clinical and socio-43 
economic need8. 44 
Previous studies assumed common causal mechanisms for ruptured and unuruptured 45 
aneurysms, but it is also possible that their underlying risk factors and pathophysiological 46 
mechanisms are different. For example, several studies report that ruptured aneurysms 47 
causing SAH are smaller than unruptured aneurysms, suggesting that they might form rapidly 48 
and quickly rupture, potentially due to different underlying mechanisms9-14.  49 
Although many potential risk factors are associated with intracranial aneurysms (e.g. 50 
aneurysm location, aneurysm size, smoking, number of aneurysms, age, female sex, 51 
hypertension, hypercholesterolemia, previous history of SAH, heart disease, and aspirin use2, 52 
8, 15-28), most show inconsistent results,29, 30 which might in part relate to rupture status. We 53 
therefore tested the hypothesis that incidentally detected unruptured aneurysms have different 54 
characteristics and risk factor profiles compared to aneurysms that cause SAH.  55 
 56 
METHODS 57 
 58 
Patients 59 
We collected data from patients with aneurysmal SAH or unruptured aneurysm without 60 
previous SAH enrolled in the Genetic and Observational Subarachnoid Haemorrhage (GOSH) 61 
study (designed to examine the genetic and clinical characteristics of patients with ruptured 62 
and unruptured aneurysms), which recruited at 22 neurosurgical centres in the UK between 63 
2011-2014. Written informed consent was obtained from participants, or from a 64 
representative in case of lack of capacity. We excluded patients with perimesencephalic SAH 65 
(63 patients) (defined by the characteristic distribution of blood (i.e. mainly or only in the 66 
cisterns around the midbrain) and absence of an identified intracranial aneurysm by the local 67 
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principle investigator)31-33 and SAH due to trauma or mycotic aneurysms. Recruitment was as 68 
inpatient or from outpatient neurovascular clinics following either new diagnosis or previous 69 
diagnosis as an inpatient. Standardised case report forms were completed by trained stroke 70 
research practitioners. Medical history was obtained from patient self-reporting and/or 71 
available medical records. Hypertension, hypercholesterolemia and diabetes mellitus were 72 
defined as present if the patient or medical records indicated hypertension, 73 
hypercholesterolemia or hyperglycaemia for which either drug treatment, lifestyle or other 74 
advice had been provided. We defined antihypertensive drug use, statin use, and aspirin use 75 
by patient self-reporting or available documentation on regular intake at the time of either 76 
admission with aneurysmal SAH or of being diagnosed with an unruptured aneurysm. 77 
Recreational drug use was assessed for cocaine, cannabis, amphetamine and opiates by patient 78 
self-reporting or from relatives. Smoking and alcohol use were defined as on-going use. 79 
Family history of aneurysmal SAH and intracranial aneurysm was defined as presence of at 80 
least one relative with the relevant disorder. Internal carotid artery location was considered as 81 
an aneurysm in the cavernous segment of the internal carotid artery and onwards. The study 82 
was approved by a Research Ethics committee.  83 
 84 
Statistical analysis 85 
Demographic, clinical and radiological data were first assessed in univariable analysis 86 
comparing patients with aneurysmal SAH to those with unruptured aneurysm [Table 1]. 87 
Variables for multivariable analysis were chosen based on univariable analysis, as well as 88 
previous studies and biological plausibility. We conducted a multivariable backward stepwise 89 
logistic regression analysis to identify factors independently associated with aneurysmal 90 
SAH. We excluded family history of SAH or unruptured aneurysm and previous history of 91 
stroke from the multivariable analysis, due to potential selection bias in the unruptured 92 
aneurysm group16. A sensitivity analysis was conducted including these variables. As a 93 
further sensitivity analysis, we used multiple imputation for missing data values. The level of 94 
statistical significance was set at 5% (p-value=0.05). Statistical analysis was performed using 95 
STATA 13 (StataCorp. 2011. Stata Statistical Software: Release 13. College Station, TX: 96 
StataCorp LP).  97 
 98 
RESULTS 99 
Baseline characteristics are summarized in Table 1. We included 2334 patients: 1729 with 100 
ruptured intracranial aneurysms (1215 females [70.3%], 514 males [29.7%], mean age 53.24, 101 
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12.70 SD) and 605 patients with unruptured aneurysms (425 females [70.25%], 180 males 102 
[29.75%] mean age 57.03, 12.17 SD).  103 
 104 
Associations of potential risk factors with incidental intracranial aneurysms and 105 
aneurysmal SAH 106 
In univariable analysis factors associated with aneurysmal SAH as opposed to incidentally-107 
detected unruptured aneurysms were: hypertension not treated (OR 2.54; 1.65-3.93 95% CI; p 108 
<0.001), ethnicity (black ethnicity (compared to the baseline group [white ethnicity]), OR 109 
2.31; 1.37-3.90 95% CI; p=0.003); smoking (OR 1.31; 1.09-1.59 95% CI; p=0.005); 110 
recreational drug use (OR 1.73; 1.09-2.90 95% CI; p=0.02); aneurysm location (anterior 111 
cerebral artery and anterior communicating artery, posterior communicating artery, and 112 
posterior circulation (compared to aneurysms of the middle cerebral artery) with location in 113 
the anterior cerebral artery or anterior communicating artery having the largest impact [OR 114 
3.50; 2.64-4.64 95% CI]) [Table 1]. Factors that were inversely associated with aneurysmal 115 
SAH (i.e. which were apparently protective) were: older age at diagnosis (as a continuous 116 
variable OR 0.98; 0.97-0.98 95% CI; p <0.001; as a categorical variable by every 10 year 117 
increase of age the odds ratio of aneurysm rupture status was 0.21; 0.14-0.26 95% CI); 118 
hypertension (OR 0.53; 0.44-0.64 95% CI; p <0.001); anti-hypertensive medication use (OR 119 
0.45; 0.37-0.54 95% CI; p <0.001); hypercholesterolemia (OR 0.45; 0.37-0.55 95% CI; p 120 
<0.001); statin medication use (OR 0.40; 0.33-0.50 95% CI; p <0.001); diabetes mellitus (OR 121 
0.60; 0.40-0.90 95% CI; p=0.013); previous stroke (OR 0.18; 0.12-0.26 95% CI; p <0.001); 122 
angina (OR 0.45; 0.27-0.77 95% CI; p=0.002); heart disease (OR 0.53; 0.35-0.81 95% CI; 123 
p=0.003); use of aspirin (OR 0.22; 0.17-0.28 95% CI; p <0.001), positive family history of 124 
intracranial aneurysm or SAH (OR 0.63; 0.49-0.80 95% CI; p <0.001;  [positive family 125 
history of aneurysmal SAH separately (OR 0.79; 0.69-0.90 05% CI; p=0.001), positive family 126 
history of unruptured intracranial aneurysm separately (OR 0.66; 0.54-0.81 95% CI; p 127 
<0.001]), location of aneurysm in the internal carotid artery (OR 0.47; 95% CI 0.35-0.62); 128 
and aneurysm size (OR 0.91; 0.90-0.93 95% CI; p <0.001; 406 missing values). For the 129 
univariable analysis we also analysed aneurysm size as a categorical variable dividing it into 130 
5mm step categories, which also showed that larger aneurysms are independently associated 131 
with a decreased risk of aneurysmal SAH (coefficient -0.089; -0.11-(-0.07) 95% CI; p <0.001.  132 
 133 
Most aneurysms were smaller than 7.0 mm. Unruptured aneurysms tended to be larger (mean 134 
aneurysm size 9.0mm, SD 6.3mm; median 7.0mm) compared to ruptured aneurysms (mean 135 
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aneurysm size 6.6mm, 4.2mm SD; median 5.7mm). The mean duration of antihypertensive 136 
treatment was 8.12 years (7.81 SD; median 5); however, this was not associated with 137 
aneurysmal SAH in the univariable analysis (OR 1.00; 0.98-1.02 95% CI; p=0.977).  138 
 139 
Of 119 patients with recreational drug use, 93 reported consumption of cannabis, 30 cocaine, 140 
17 ecstasy, and 5 opiates. Forty-one patients had consumed multiple drugs.  141 
 142 
In the multivariable regression analysis, following factors were independently associated with 143 
aneurysmal SAH in the final adjusted model [Table 2]: black ethnicity compared to white 144 
ethnicity (OR 2.42; 1.29-4.56 95 % CI; p=0.013 overall categorical variable); and aneurysm 145 
location (location in the posterior communicating artery had the largest influence [OR 3.92; 146 
2.67-5.74 95% CI]; p <0.001 overall categorical variable; internal carotid artery location was 147 
inversely associated with aneurysmal SAH status). Independent factors inversely associated 148 
with aneurysmal SAH status were: treatment with antihypertensive medication (OR: 0.65; 149 
0.49-0.84 95% CI; p=0.001); hypercholesterolemia (OR 0.64; 0.48-0.85 95% CI; p=0.002); 150 
aspirin use (OR 0.28; 0.20-0.40 95% CI; p <0.001); increasing aneurysm size (OR 0.76, 0.69-151 
0.84 95% CI; p <0.001), and internal carotid artery location (OR 0.53; 0.38-0.75 95% CI).  152 
 153 
In a sensitivity analysis including family history of aneurysm and previous history of stroke in 154 
the final model, the associations with aneurysmal SAH did not significantly change; Asian 155 
ethnicity became a significant predictor for aneurysmal SAH ([OR 2.13; 1.02-4.46 95% CI], 156 
p=0.012 overall categorical variable), and the model’s prediction increased (likelihood ratio 157 
test p <0.001, Pseudo R2 increasing from 0.18 to 0.20) [Table 3]. A further sensitivity 158 
analysis using multiple imputation for missing data in the variables aneurysm size (406 159 
missing values) and aneurysm location (148 missing values) showed no change in OR (data 160 
not shown).  161 
 162 
 163 
DISCUSSION 164 
In this large observational study, we show patients with incidentally detected unruptured 165 
intracranial aneurysms have different patient and aneurysm characteristics and potential risk 166 
factors compared to patients with ruptured aneurysms. Certain aneurysm locations (anterior 167 
cerebral artery and anterior communication artery, posterior communicating artery, and 168 
posterior circulation) and black ethnicity were independently associated with aneurysmal 169 
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SAH, compared to patients with an unruptured aneurysm. In addition, we found that location 170 
in the internal carotid artery is inversely associated with aneurysmal SAH. We also 171 
demonstrated antihypertensive medication use, aspirin use, hypercholesterolemia, and larger 172 
aneurysm size are independently associated with a decreased risk of aneurysmal SAH 173 
compared to the population of incidental intracranial aneurysms.  174 
 175 
In our cohort, incidentally detected unruptured aneurysms were larger compared to those with 176 
aneurysmal SAH. Our findings are consistent with other studies that show the majority of 177 
ruptured aneurysms are less than 10 mm12, 14, 34, 35. Indeed, in our study the size of unruptured 178 
aneurysms was larger than that reported in a previous meta-analysis1. This could indicate 179 
selection bias, a limitation of any hospital-based study. However, an important strength is that 180 
we have data on unruptured aneurysm size in 544 patients (90%); in the meta-analysis this 181 
was only available in 368 patients (25%)1.  182 
 183 
Also in line with our data, is the International Study of Unruptured Intracranial Aneurysms 184 
(ISUIA), a lower risk of rupture was reported in intracranial aneurysms with a diameter of 185 
less than 10 mm; this observation that small unruptured aneurysms are at lower risk of future 186 
rupture than large unruptured aneurysms has been convincingly shown in other large 187 
prospective studies20, 36, 37. One explanation for this apparent inconsistency is that aneurysms 188 
that rupture to cause SAH and incidentally detected unruptured aneurysms have different 189 
pathological mechanisms making them behave differently38. Most intracranial aneurysms are 190 
considered to form over days to weeks, at which point they either rupture or stabilise due to 191 
remodelling of the arterial wall10, 11. Whether early rupture or stabilisation occurs might be 192 
because of different underlying pathological haemodynamic and inflammatory mechanisms39. 193 
Indeed, differences have been described in the histology of ruptured compared to unruptured 194 
aneurysms9, 10. Our data are consistent with this hypothesis, in which rapidly developing 195 
aneurysms that rupture are expected to be small. By contrast, the majority of stable 196 
unruptured aneurysms would be expected to have low rupture rates, even if rupture rate is 197 
higher in larger aneurysm compared to smaller aneurysms1, 3, 39, 40. Nevertheless, patients 198 
whose unruptured aneurysm increase in size during follow-up are at high risk of rupture and 199 
warrant further treatment41, 42. An alternate explanation is that our results are due to selection 200 
bias. One could hypothesise that larger ruptured aneurysms were excluded due to prehospital 201 
death if they suffered more severe haemorrhages, while smaller unruptured aneurysms were 202 
excluded as they may not have been referred to tertiary care. Therefore, only tentative 203 
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conclusions can be drawn from this result and its meaning must be considered carefully. This 204 
could only be resolved in a longitudinal prospective large trial. However, a population of 205 
patients with unruptured aneurysms as in ISUIA and other studies would not suffice and it 206 
would require a healthy population with no prior diagnosis of an aneurysm. Due to the 207 
relatively low incidence of aneurysms and particularly SAH these would be logistically 208 
challenging.  209 
 210 
The large sample size allowed us to investigate not only risk factors but also their treatments. 211 
A previous study has found a linear relationship between increase in systemic arterial pressure 212 
and pressure in the aneurysm sac43. This finding supports the hypothesis that a rapid increase 213 
in blood pressure rather than a chronic increased blood pressure lead to aneurysm rupture. 214 
Patients with untreated hypertension had a higher OR for rupture. Furthermore, treatment 215 
rather than duration of treatment, appears to be associated with a decrease in aneurysmal 216 
SAH. These findings are most consistent with a rapid benefit from antihypertensive treatment, 217 
rather than a long-term remodelling of the aneurysm wall. The potentially protective effect of 218 
treatment is consistent with the hypothesis that a sudden rise in blood pressure might trigger 219 
the rapid formation of aneurysms that are prone to rupture early. Different antihypertensive 220 
drugs with different mechanisms of action might have differing influences on aneurysm 221 
formation and rupture other than purely through blood pressure control44. However, we did 222 
not have data on specific antihypertensive agents, which should ideally be addressed in 223 
further prospective studies. 224 
 225 
We found that regular aspirin use was significantly less common in patients with SAH than in 226 
patients with unruptured aneurysms even after fully adjusting for potential confounders 227 
(ischaemic heart disease, peripheral vascular disease, and diabetes; OR 0.28; 95% CI 0.20-228 
0.40; p<0.001). This could mean that aspirin use protects against SAH in patients with 229 
unruptured aneurysms. Although it is possible that the use of aspirin results in more severe 230 
SAH, which might be excluded from our study (e.g. if patients die before reaching hospital), 231 
we did not find any association between aspirin use and severity of SAH (data not shown). 232 
Thus, this seems an unlikely explanation for the higher proportion of patients taking aspirin in 233 
the unruptured aneurysm group (25.45% versus 6.94% in the aneurysmal SAH group). A 234 
recent study also showed no association of aspirin or anticoagulation with mortality or 235 
complications; on the contrary, aspirin was associated with a shorter hospital stay45; other 236 
studies showed a potential decrease in ischaemic events after SAH and increase in 237 
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asymptomatic survival46, 47. However, further studies suggest aspirin given preventively might 238 
increase the risk of intracerebral haemorrhage and rebleeding after SAH46, 48, 49. Furthermore, 239 
our findings are in keeping with prospective data from the ISUIA and other studies, which 240 
showed a protective effect for regular aspirin use on intracranial aneurysm rupture25, 47. 241 
Aspirin could potentially reduce the risk of aneurysm rupture by inhibiting inflammatory 242 
mediators (e.g. matrix metalloproteinases and tumor necrosis factor-alpha)50. Our findings 243 
suggest that unruptured aneurysms are not a contraindication to antiplatelet therapy for 244 
patients with a clear indication. Due to lack of definitive strong evidence, neither for a 245 
protective effect nor harmful effect, this requires further research. Indeed, our data strengthen 246 
the case for randomised trials testing the benefit of regular aspirin use on aneurysm rupture. 247 
We cannot fully explain the reason for aspirin use being higher in the unruptured aneurysm 248 
group; apart from a true biological effect, another possibility is that patients found to have an 249 
unruptured aneurysm are investigated for additional diseases that lead to aspirin prescription 250 
(e.g. hypertension, hypercholesterolaemia or previous stroke).  251 
 252 
Our study also suggests that hypercholesterolaemia could have a protective effect on 253 
aneurysm rupture (OR 0.64; 95% CI 0.48-0.85; p=0.002). Previous smaller studies found a 254 
similar relationship, but were unable to determine whether this finding might be due to statin 255 
treatment rather than the underlying hypercholesterolaemia16, 51. We were able to adjust for 256 
use of statins, and showed that hypercholesterolaemia was a protective factor for aneurysmal 257 
SAH, independent of the use of statin medications. The mechanism remains unclear. We 258 
suggest that part of the effect could emerge through stabilisation of the aneurysm wall and so 259 
preventing newly formed aneurysm from early rupture. 260 
 261 
We found black ethnicity to be independently associated with aneurysmal SAH, but whether 262 
this is due to genetic or environmental factors remains uncertain. Greater risk of aneurysmal 263 
SAH in black patients compared to white patients has been described before52. Another study 264 
found that patients who underwent treatment for unruptured aneurysms generally had higher 265 
socioeconomic status and were more likely to be white, female, or insured, suggesting the 266 
findings to be due to social implemented reasons rather than based on genetic differences53. 267 
 268 
Our study has important strengths. We included a large sample from multiple neurosurgical 269 
centres throughout the UK. The participants with aneurysmal SAH and unruptured aneurysms 270 
were recruited from the same hospitals over the same time-period using standardized 271 
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inclusion criteria and report questionnaire with standardized definitions of all risk factors. 272 
Moreover, the unruptured aneurysm group is free of the disease (aneurysmal SAH). Our large 273 
sample size allowed us to undertake a multivariable analysis including many clinical and 274 
anatomical factors in our model.  275 
 276 
Our study also has limitations. Selection bias towards patients with unruptured intracranial 277 
aneurysms with a family history of intracranial aneurysm or aneurysmal SAH, or with a 278 
previous stroke has been suggested (as these patients will be more likely to undergo brain 279 
imaging)16. Indeed, common reasons for intracranial aneurysm screening were positive family 280 
history for aneurysmal SAH or unruptured aneurysm, or a previous history of stroke; 18.35% 281 
of the unruptured aneurysm patients had a positive family history of SAH or intracranial 282 
aneurysms compared to 12.32% with aneurysmal SAH (p <0.001). 11.9% of the patients with 283 
unruptured aneurysms had a previous history of stroke compared to 2.3% of those with 284 
aneurysmal SAH (p <0.001). Nevertheless, a sensitivity analysis controlling for these 285 
variables did not affect our findings [Table 3]. As the aim of our study was not to compare 286 
“risk factors” between two groups with the same underlying disease but to evaluate for 287 
differing characteristics and potential risk factors in two different diseases, selection bias 288 
should be negligible. The study was designed to examine the different genetic and clinical 289 
characteristics of patients with ruptured and unruptured aneurysms; we are here presenting the 290 
large amount of clinical data collected to explore clinical differences between these cohorts. 291 
Another limitation arises from the fact that patients who are diagnosed with an unruptured 292 
intracranial aneurysm might not be seen by a neurologist or neurosurgeon due to their 293 
advanced age or significant comorbidities. These patients could not be included in our study.  294 
We did not explicitly collect the information about why unruptured intracranial aneurysms 295 
were diagnosed, apart from the small symptomatic number (9 patients). The study also has 296 
potential for bias towards aneurysmal SAH survivors; patients who died before they could be 297 
recruited, or in whom no informant could provide consent, were excluded from our study. 298 
Another potential limitation of our study is the case-control design preventing any direct 299 
inferences on causality. However, an observational natural history study in a similar 300 
population of untreated intracranial aneurysms is unlikely to be either feasible or ethically 301 
acceptable; not all diagnosed unruptured aneurysms can be left untreated and be followed-up, 302 
which also introduces selection bias. Although it would be highly desirable that diagnosed 303 
unruptured aneurysms result from random screening of the population this is unlikely to 304 
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happen without large scale intracranial imaging studies, which are likely to be logistically, 305 
financially and ethically challenging.  306 
 307 
CONCLUSION 308 
We found that patients with aneurysmal SAH most likely have a different risk factor profile in 309 
comparison to patients with incidentally detected unruptured aneurysms. Aneurysm location 310 
and black ethnicity are associated with aneurysmal SAH in comparison to incidentally 311 
detected unruptured aneurysms. Antihypertensive medication, aspirin use, 312 
hypercholesterolemia, aneurysm location on the internal carotid artery, and aneurysm size are 313 
associated with unruptured intracranial aneurysms compared to aneurysmal SAH. These 314 
findings support the hypothesis that risk factors for the type of aneurysm that ruptures early 315 
are different to unruptured aneurysms or to those that rupture later. The large potentially 316 
protective effect of aspirin use justifies randomized clinical trials to prevent SAH in patients 317 
with unruptured aneurysms offering an alternative treatment option in small aneurysms, 318 
where the decision for invasive treatment is difficult. This would also hopefully resolve the 319 
controversial evidence on protective or harmful effects of aspirin.  320 
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 Table 1: Characteristics of the cohort and results of univariable analysis 
 
Variable 
Ruptured 
aneurysm 
 
Unruptured 
aneurysm 
 
OR; 95% CI p-value 
Age, (mean) y 53.2 (12.7 SD) 57.0 (12.2 SD) 
0.98; 0.97-
0.98 
<0.001 
Gender   1.0; 0.82-1.22 0.99 
Male 514 (29.7%) 180 (29.8%)   
Female 1215 (70.3%) 425 (70.3%)   
Ethnicity    0.002 
-White 1484 (87.91) 551 (93.39%)   
- Mixed 26 (1.54%) 5 (0.85%) 
1.93; 0.74-
5.05 
 
- Asian 72 (4.27%) 17 (2.88%) 
1.57; 0.92-
2.69 
 
- Black 106 (6.28%) 17 (2.88%) 
2.32; 1.37-
3.90 
 
Family history     
Positive Family 
History SAH/UIA 
213 (12.3%) 111 (18.4%) 
0.63; 0.49-
0.80 
<0.001 
Positive Family 
History of SAH 
191 (11.1%) 98 (16.2%) 
0.79; 0.69-
0.90 
0.001 
Positive Family 
History of UIA 
25 (1.5%) 19 (3.1%) 
0.66; 0.54-
0.81 
<0.001 
Smoker 765 (44.3%) 228 (37.7%) 
1.31; 1.09-
1.59 
0.005 
Drinker 1168 (67.6%) 392 (64.8%) 
1.13; 0.93-
1.37 
0.215 
Recreational drug use 99 (5.7%) 20 (3.3%) 
1.78; 1.09-
2.90 
0.02 
Medical History     
Table 1
Hypertension 542 (31.4%) 281 (46.5%) 
0.53; 0.44-
0.64 
<0.001 
Hypertension not 
treated 
123 (80.9%) 29 (19.1%) 
2.54; 1.65-
3.93 
<0.001 
Antihypertensive 
Medication 
425 (24.6%) 255 (42.2%) 
0.45; 0.37-
0.54 
<0.001 
Hypercholesterolemia 350 (20.2%) 218 (36.0%) 
0.45; 0.37-
0.55 
<0.001 
Statin medication 273 (15.8%) 192 (31.7%) 
0.40; 0.33-
0.50 
<0.001 
Diabetes Mellitus 69 (4.0%) 39 (6.5%) 
0.60; 0.40-
0.90 
0.013 
Previous Stroke 40 (2.3%) 72 (11.9%) 
0.18; 0.12-
0.26 
<0.001 
Previous ICH 9 (0.5%) 4 (0.7%) 
0.79; 0.24-
2.56 
0.75 
History of 
Myocardial infarction 
41 (2.4%) 19 (3.1%) 
0.75; 0.43-
1.30 
0.304 
Coronary artery 
disease (Angina) 
33 (1.9%) 25 (4.13%) 
0.45; 0.27-
0.77 
0.002 
Cardiac disease 
(myocardial 
infarction and angina) 
58 (3.4%) 37 (6.1%) 
0.53; 0.35-
0.81 
0.003 
Peripheral vascular 
disease 
25 (1.5%) 15 (2.5%) 
0.58; 0.30-
1.10 
0.09 
Aspirin 120 (6.94%) 154 (25.45%) 
0.22; 0.17-
0.28 
<0.001 
Aneurysm location    <0.001 
- MCA 341 (21.04%) 194 (34.34%)   
- ICA 135 (8.33%) 164 (29.03%) 
0.47; 0.35-
0.62 
 
- ACA/Acom 572 (35.29%) 93 (16.46%) 
3.50; 2.64-
4.64 
 
- Pcom 359 (22.15%) 63 (11.15%) 3.24; 2.35-  
SD = standard deviation; ICH = intracerebral haemorrhage; MCA = middle cerebral artery; 
ICA = internal carotid artery; ACA = anterior cerebral artery; Acom = anterior 
communicating artery; Pcom = posterior communicating artery. 
For aneurysm location there were 40 missing values in the ruptured and 108 in the unruptured 
group 
For aneurysm size there were 345 missing values in the ruptured and 61 in the unruptured 
group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.47 
- Posterior circulation 214 (13.20%) 51 (9.03%) 
2.39; 1.68-
3.40 
 
Aneurysm size 
(mean) mm 
6.6 (4.16 SD) 9.0 (6.3 SD) 
0.91; 0.90-
0.93 
<0.001 
Multiple aneurysms 447 (25.9%) 161 (26.6%) 
0.96; 0.78-
1.19 
0.714 
Table 2:  Multivariable analysis model evaluating differences between unruptured and 
ruptured intracranial aneurysms 
 
  
Odds Ratio 
 
95% CI 
 
P  value 
 
Age 1.0 0.98-1.01 0.365 
 
Sex (male vs female) 0.86 0.66-1.11 0.242 
 
Ethnicity   0.013 
- white (reference)    
- black 2.42 1.29-4.56  
- asian 2.00 0.98-4.08  
- mixed 1.26 0.45-3.53  
Smoker 1.22 0.96-1.56 0.104 
 
Use of antihypertensive 
medication 
 
   0.65 0.49-0.84 0.001 
Hypercholesterolemia    0.64 0.48-0.85 0.002 
 
Aspirin use    0.28 0.20-0.40 <0.001 
 
Aneurysm location    
- MCA (reference)    
- ICA 0.53 0.38-0.75  
- ACA/Acom 3.21 2.34-4.40  
- Pcom 3.92 2.67-5.74  
- Posterior circulation 3.12 2.08-4.70  
Aneurysm size      0.76 0.69-0.84 <0.001 
    
 
Table 2
MCA = middle cerebral artery; ICA = internal carotid artery; ACA = anterior cerebral artery; 
Acom = anterior communicating artery; Pcom = posterior communicating artery. 
 
Table 3:  Multivariable analysis model, sensitivity analysis including positive family 
history of SAH or unruptured intracranial aneurysm and previous history of stroke 
 
  
Odds Ratio 
 
95% CI 
 
P value 
 
Age 1.0 0.98-1.01 0.392 
 
Sex 0.83 0.64-1.08 0.171 
 
Ethnicity   0.012 
- white (reference)    
- black  2.41 1.27-4.56  
- asian 2.13 1.02-4.46  
- mixed 1.20 0.43-3.38  
Antihypertensive medication 0.69 0.52-0.90 0.007 
 
Hypercholesterolemia 0.69 0.52-0.92 0.011 
 
Aspirin use 
 
0.32 0.22-0.45 <0.001 
Aneurysm location   <0.001 
- MCA (reference)    
- ICA 0.533 0.38-0.75  
- ACA/Acom 3.23 2.34-4.44  
- Pcom 4.07 2.75-6.01  
- Posterior circulation 3.12 2.06-4.72  
Aneurysm size 0.76 0.69-0.84 <0.001 
 
Positive Family History 0.61 0.44-0.85 <0.001 
 
Previous Stroke 0.24 0.14-0.41 <0.001 
    
Table 3
MCA = middle cerebral artery; ICA = internal carotid artery; ACA = anterior cerebral artery; 
Acom = anterior communicating artery; Pcom = posterior communicating artery. 
 
 
 
